Paul C - Search Results

1

Expression of glutathione transferase pi as a predictor for treatment results at different stages of acute nonlymphoblastic leukemia.

Tidefelt U, Elmhorn-Rosenborg A, Paul C, Hao XY, Mannervik B, Eriksson LC. Tidefelt U, et al. Among authors: paul c. Cancer Res. 1992 Jun 15;52(12):3281-5. Cancer Res. 1992. PMID: 1596886

2

Intracellular uptake and cytotoxic effect in vitro of doxorubicin and epirubicin in human leukemic and normal hematopoietic cells.

Tidefelt U, Sundman-Engberg B, Paul C. Tidefelt U, et al. Among authors: paul c. Cancer Chemother Pharmacol. 1991;29(1):7-12. doi: 10.1007/BF00686328. Cancer Chemother Pharmacol. 1991. PMID: 1742852

3

Intracellular concentrations of anti cancer drugs in leukemic cells in vitro vs in vivo.

Sundman-Engberg B, Tidefelt U, Liliemark J, Paul C. Sundman-Engberg B, et al. Among authors: paul c. Cancer Chemother Pharmacol. 1990;25(4):252-6. doi: 10.1007/BF00684881. Cancer Chemother Pharmacol. 1990. PMID: 2295112

4

In vitro drug testing in patients with acute leukemia with incubations mimicking in vivo intracellular drug concentrations.

Tidefelt U, Sundman-Engberg B, Rhedin AS, Paul C. Tidefelt U, et al. Among authors: paul c. Eur J Haematol. 1989 Nov;43(5):374-84. doi: 10.1111/j.1600-0609.1989.tb00323.x. Eur J Haematol. 1989. PMID: 2482193 Clinical Trial.

5

Pharmacokinetics of daunorubicin and doxorubicin in plasma and leukemic cells from patients with acute nonlymphoblastic leukemia.

Paul C, Liliemark J, Tidefelt U, Gahrton G, Peterson C. Paul C, et al. Ther Drug Monit. 1989;11(2):140-8. doi: 10.1097/00007691-198903000-00004. Ther Drug Monit. 1989. PMID: 2718219

6

Comparison of the intracellular pharmacokinetics of doxorubicin and 4'-epi-doxorubicin in patients with acute leukemia.

Tidefelt U, Sundman-Engberg B, Paul C. Tidefelt U, et al. Among authors: paul c. Cancer Chemother Pharmacol. 1989;24(4):225-9. doi: 10.1007/BF00257622. Cancer Chemother Pharmacol. 1989. PMID: 2752502

7

Increasing the accumulation of daunorubicin in human leukemic cells by prolonging the infusion time.

Paul C, Tidefelt U, Liliemark J, Peterson C. Paul C, et al. Leuk Res. 1989;13(2):191-6. doi: 10.1016/0145-2126(89)90145-8. Leuk Res. 1989. PMID: 2927175

8

Pharmacokinetics of mitoxantrone, etoposide and cytosine arabinoside in leukemic cells during treatment of acute myelogenous leukemia--relationship to treatment outcome and bone marrow toxicity.

Gruber A, Liliemark E, Tidefelt U, Paul C, Björkholm M, Peterson C, Liliemark J. Gruber A, et al. Among authors: paul c. Leuk Res. 1995 Oct;19(10):757-61. doi: 10.1016/0145-2126(95)00061-r. Leuk Res. 1995. PMID: 7500654

9

Increased intracellular concentrations of doxorubicin in resistant lymphoma cells in vivo by concomitant therapy with verapamil and cyclosporin A.

Tidefelt U, Juliusson G, Elmhorn-Rosenborg A, Peterson C, Paul C. Tidefelt U, et al. Among authors: paul c. Eur J Haematol. 1994 May;52(5):276-82. doi: 10.1111/j.1600-0609.1994.tb00096.x. Eur J Haematol. 1994. PMID: 8020627

10

Comparison of the intracellular pharmacokinetics of daunorubicin and idarubicin in patients with acute leukemia.

Tidefelt U, Sundman-Engberg B, Paul C. Tidefelt U, et al. Among authors: paul c. Leuk Res. 1994 Apr;18(4):293-7. doi: 10.1016/0145-2126(94)90032-9. Leuk Res. 1994. PMID: 8170171

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,187 results

Search Page

Filters